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1. Introduction
In North America and Europe, cancer involving the central nervous system (CNS) ranks
second as the most common malignancy seen in infancy through adolescence, second only to
leukaemia [1-7]. Consistent with this are figures on cancer-related mortality. In the year 2004,
for example, there were 566 confirmed cases of leukemia-related death among children in the
United States, followed by 555 CNS cancer-related deaths; these numbers accounted for 25.5%
and 25.0% of the total number of cancer deaths in individuals less than 20 years old, respec‐
tively [4].
In general, survival from cancer has improved dramatically over the past forty years, pre‐
sumably due to a combination of improved treatments and earlier detection. This is especially
true in the paediatric population, among whom the overall long-term survival rate across all
cancers has risen from under 50% to roughly 70% [4;8;9]. Even with brain cancer, the prognosis
in children has improved, such that long-term survival is now achieved in more than half of
patients [10]. This being said, the neoplasm originates in the brainstem in roughly 10-20% of
children with CNS cancer [7;11-13], accounting for 150 to 300 new cases per year in the U.S.
[11;13] and thus rendering it more common in children and adolescents than in adults [14;15].
And in this subset of children, the prognosis generally is considered extremely bleak, akin to
that of glioblastoma multiforme [1;4;14;16-19].
Despite a continued poor prognosis, much has changed over the past several decades — like
how paediatric brainstem tumours are diagnosed and classified, if and when surgery is
considered, approaches to surgery, the use of adjunct therapies like radiation and chemother‐
apy, and the evolution of several new therapeutic options. Once lumped together as a single
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entity that was considered inoperable and, hence, completely incurable, recent developments
in imaging and surgical techniques have led to the classification of several different types of
brainstem tumour; and, for some of these, surgical resection is considered the treatment of
choice [16;18;20].
This chapter reviews the historical progression of understanding of paediatric brainstem
tumours, including evolving beliefs regarding their classification, diagnosis, management,
prognosis and prognosticators, dating from the 1970s to current times. It then describes current
diagnostic and management protocols for these tumours, ending with a glance forwards
towards potentially promising treatments and technologies and how they might, hopefully
within the near future, favourably alter outcomes in these patients, both in terms of their
survival and quality of life.
2. Where we have been
2.1. Definitions, diagnosis and classification
The brainstem has been defined as extending from the midbrain (tectal plate) to the medullary
cervical junction [7]. Brain stem tumours are, by definition, tumours that involve the brainstem.
However, they include tumours not just in the brainstem per se, but also in the upper cervical
spine [16]. In the paediatric population, posterior fossa tumours significantly outnumber those
that are supratentorial [10;21;22], and brainstem tumours account for roughly 25% of all
tumours found within the posterior fossa [16;23]. The vast majority of these are primary lesions,
since just 3 to 5% of all brain metastases are found in the brainstem [24]. The most common
paediatric posterior fossa tumours are cerebellar astrocytomas, medulloblastomas, ependy‐
momas and brainstem gliomas [25].
Traditionally, the term brainstem glioma has been used to incorporate all brainstem tumours,
largely because biopsies often were not performed and the majority of brainstem tumours in
childhood are, in fact, of glial cell origin [26;27]. However, other histological forms of tumours
do exist, though they comprise but a small percentage of brainstem tumours, and generally
tend to be exophytic, growing either external to the brainstem or on its surface. Even among
such exophytic tumours, gliomas form the clear majority. In their series of 75 paediatric
patients with exophytic tumours seen between 1970 and 1990, Pierre-Kahn et al. [28] noted 69
glial tumours (92% of the total), of which 58 were astrocytomas and 11 oligodendrogliomas.
The remaining six non-glial tumours were two ependymomas; two primitive neuroectodermal
tumours (PNET); one ganglioglioma; and one of unknown histology [28]. In a much more
recent review of non-glial brainstem tumours, other brainstem lesions noted to occur anecdo‐
tally included medulloblastomas invading the brainstem, cavernomas, lymphomas, haeman‐
gioblastomas, and other ganglionic and mixed tumors [29]. Nonetheless, many continue to use
the term brainstem glioma generically, given that the vast majority of brainstem tumours are
glial cell based.
Up until the development of advanced imaging techniques — like computed tomography (CT)
and, to an even greater extent, magnetic resonance imaging (MRI) — brainstem tumours
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tended to be lumped together as a single clinical entity and considered uniformly inoperable
[30]. Since they were presumed gliomas and surgery was deemed contraindicated, there was
no call even to biopsy them, except in certain instances in which the diagnosis was in doubt.
For example, in 1969, Matson wrote: “brainstem gliomas must be classified as malignant
tumors since their location in itself renders them inoperable” [21]. And as late as 1984, Tomita
et al. [31] wrote: “Since biopsy specimens often misrepresent the true pathology... surgery
undertaken to obtain precise histological verification of brain stem gliomas is futile.” Instead,
these latter authors recommended computed tomography (CT) with high-resolution metriza‐
mide CT cisternography to distinguish surgically resectable extra-axial tumors adjacent to the
brain stem from non-resectable intrinsic brain stem gliomas. Such sentiments — that tumours
only were worth a biopsy if they were either completely exterior to brainstem tissue or, at
worst, on the surface — were echoed by others [32]. Consequently, early classification of
brainstem tumours often subdivided lesions into those that were exclusively or primarily intra-
axial, and those that were exclusively or primarily extra-axial. Meanwhile, brainstem tumours
were collectively contrasted against those involving the midbrain or thalamus, both of which
exhibited considerably superior prognoses [33].
This being said, there were early reports of certain patients with brainstem tumours who
survived long-term. For example, in 1971, Lassiter et al. reported on 37 patients with presumed
brainstem gliomas (22 of them children), among whom there were four children with large,
surgically-drained neoplastic cysts who achieved long-term survival: two of these children
died 7½ and 13 years later, and two still were alive 8½ and 9 years post diagnosis, one of them
going on to graduate from college and the other with residual hemiparesis and mental
retardation [34]. In 1975, Hara et al. reviewed the cases of 24 brainstem gliomas, and found
that the median survival was 9 months, except for one patient who survived beyond 4½ years
and another who lived for 14 years and 10 months before succumbing to the disease [35].
Similar isolated cases of long-term survival with brainstem gliomas, especially cystic lesions,
were reported as far back as 1937 and 1940 through the mid nineteen seventies and early
eighties [36-42]. And, contrary to conventional wisdom, even then, some neurosurgeons were
routinely performing biopsies and surgery on select patients with brainstem gliomas
[27;40;41;43-46].
In the nineteen sixties and early nineteen seventies, angiography and pneumoencephalograms
were largely used to identify brain and brainstem tumours [47-50]. These imaging modalities
were replaced in the mid nineteen seventies as computed tomography (CT) emerged as the
imaging tool of choice for the detection and diagnosis of both supra-and infra-tentorial lesions,
including brainstem tumours [51-54]. By this point, some surgeons were starting to distinguish
outcomes between different subsets of patient who were able to undergo either partial or
radical resection of brainstem cancers [27;40;41;43-45]. The first to propose what he termed a
staging system for brainstem gliomas was Epstein, in 1985, who first categorized tumours as
intrinsic, exophytic and disseminated; and then subcategorized intrinsic (actual brainstem)
tumours as either diffuse, focal or cervico-medullary [43]. In 1986 and again in 1988, Epstein
et al. published series of paediatric patients undergoing surgery for brainstem cancer, again
classifying patients as focal, diffuse or cervico-medullary; in the latter report, they added a
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category for cystic lesions [27;44]. What these authors noted was uniformly dismal outcomes
in children with diffuse lesions, but often favourable outcomes in those patients with any one
of the three other classifications. In the 1988 report, co-authored by Wisoff [27], among 66
children with intrinsic brainstem gliomas diagnosed between 1980 and 1986 who underwent
radical surgical resection and either CT, MRI or both pre-operatively, 27 (41%) were found to
have diffuse tumors, all of whom died within 12 to 18 months of surgery with malignant
neoplasms that had not benefitted from surgery. However, five of nine children with cystic
tumors, three of five with focal tumors, and twenty of twenty-four with cervicomedullary
tumors were discovered to have a histopathologically low-grade lesion, and these 28 children
all remained alive between one and six years post-operatively. The authors proposed criteria
combining clinical and neuroradiological findings to predict which patients with brainstem
tumors were likely to benefit from radical surgical intervention [27].
Since that time, several additional and very different classification systems have been proposed
for brainstem tumours, including those by Stroink et al., Barkovich et al., Albright, Fischbein
et al., Choux et al., Fisher et al., Mehta et al. and, most recently, Ramos et al. [45;55-61]. (See
Table 1) The system proposed by Stroink et al., published in 1987, was born out of a study of
16 children (9 girls, 7 boys; age range 1½-12 years) with dorsally exophytic transependymal
benign brainstem gliomas diagnosed between 1962 and 1985 at Sick Kids Hospital in Toronto,
Canada [45]. Of these, 13 were low-grade (grade I-II) astrocytomas, one a grade III astrocytoma,
and two gangliogliomas. All 16 patients underwent subtotal resection of their tumours, and
seven had post-operative radiation therapy. One died 18 months after surgery, but the
remaining 15 remained alive an average of eight years post-operatively (median=7 years;
range=8 months to 23 years). Based upon these results, Stroink et al. proposed dorsal exophytic
gliomas (Type I) as a distinct clinical entity, to differentiate them from hypo-dense, non-
enhancing intrinsic tumours (Type IIa); hyper-dense, contrast-enhancing exophytic intrinsic
tumours (Type IIb); focal, enhancing cystic intrinsic tumours (Type III); and focal iso-dense
and contrast-enhancing intrinsic tumours (Type IV) [45].
Author(s) YearPublished Imaging Classification System
Epstein [43] 1985 CT, MRI Intrinsic - diffuse; focal, cervicomedullary
Exophytic - anterolateral; posterolateral
Disseminated - positive cytology; positive myelography
Epstein et al. [44] 1986 CT, MRI Diffuse
Focal
Cervicomedullary
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Author(s) YearPublished Imaging Classification System
Stroink et al. [45] 1987 CT with contrast Type I: dorsal exophytic glioma
Type II intrinsic brainstem tumour
* IIa - hypodense with no contrast enhancement
IIb - hyperdense with contrast enhancement, exophytic
Type III: focal cystic tumour with contrast enhancement
Type IV: focal isodense tumour with contrast enhancement
Barkovich et al. [55] 1990 MRI Tumours characterized by -
(1) Location - midbrain, pons, medulla
(2) Focality - focal or diffuse
(3) Direction & extent of tumour growth
(4) Degree of brainstem enlargement
(5) Presence/absence of exophytic growth
(6) Presence/absence of haemorrhage or necrosis
(7) Evidence of hydrocephalus
Albright [58] 1996 MRI Focal - midbrain; pons; medulla
Diffuse
Fischbein et al. [56] 1996 MRI Midbrain - diffuse; focal; tectal
Pons - diffuse; focal
Medulla - diffuse; focal; dorsal and exophytic
Choux et al. [57] 2000 MRI Type I - diffuse
Type II - intrinsic and focal
Type III - intrinsic and exophytic
Type IV - cervicomedullary
Fisher et al. [59] 2000 MRI Pilocytic astrocytomas
Fibrillary astrocytomas
Other tumors
Mehta et al. [60] 2009 MRI Intrinsic tumours - expanding; diffuse infiltrative; purely ventral
Extrinsic tumours
Ramos et al. [61] 2013 MRI Diffuse intrinsic/diffusely infiltrative




Table 1. Classification Systems for Brain Stem Tumours-1985 to Present
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It was in the mid to late nineteen-eighties that magnetic resonance imaging (MRI) started to
replace CT as the imaging modality of choice for the diagnosis and classification of brainstem
tumours [62]. As such, it was based upon MRI studies that Barkovich et al. proposed their
criteria for brainstem tumours in 1990 [55]. Their criteria were derived from the results of
retrospectively-reviewed MRI studies for 87 paediatric patients with brainstem gliomas. T2-
weighted images were deemed most appropriate for use, given that they were the most
accurate at demonstrating the extent of tumour. In this much more elaborate classification
scheme, tumours were characterized in terms of (1) their location of origin, into midbrain, pons
and medulla; (2) their degree of ‘focality’ (whether diffuse of focal); (3) the direction and extent
of tumour growth; (4) the degree of brainstem enlargement; (5) the degree of exophytic growth;
(6) the presence or absence of cysts, necrosis or hemorrhage; and (7) the presence or absence
of hydrocephalus. This classification scheme was never scientifically validated to determine
its ability to predict outcomes, however, and failed to achieve widespread acceptance. Likely
reasons for this failure were how cumbersome the system was, and the lack of any firm
guidelines as to its use.
As such, subsequent classification schemes have been much simpler, starting with those
proposed by Albright, in 1996, who returned to the very simple categorization of lesions as
being either focal (further distinguished by location, into midbrain, pons or medulla) or diffuse
[58]; and Fischbein et al., also in 1996, who again categorized lesions as focal or diffuse, but
categorized both forms of lesion by location — again into midbrain, pons or medulla [56].
Harkening back to the four-category system initially proposed by Epstein in 1985 [43], Freeman
et al., in 1998, and Choux et al., in 2000, adopted the four relatively straight-forward categories
largely in use today: diffuse intrinsic; focal intrinsic; focal exophytic, and cervicomedullary
[18;57]. In 2009, Mehta et al. proposed a modified sub-categorization of intrinsic tumours, into
expanding, diffuse infiltrative, and pure ventral varieties, achieving good surgical results and
reasonable survival with the first of the three subtypes [60]. Then, most recently, Ramos et al.
adopted yet another classification system that included ‘diffuse intrinsic and diffusely
infiltrative’ as a single category, followed by four additional categories of various focal lesions
[61]. The authors’ conclusion was that “brainstem tumors are a heterogeneous group of
tumors.” Clearly then, in terms of how brainstem tumours are now perceived, there has been
a 180 degree reversal from early statements [21;30;31] about their homogeneity and the
inappropriateness of biopsies for brainstem tumours. The questions remain, however: Who
warrants such biopsies? And how could biopsies and surgery influence outcomes?
2.2. Outcome predictors and indications for surgery
Early universal pessimism regarding the fate of children with brainstem tumours has also
clearly changed in recent years, with reports of better than 90% five-and ten-year survival rates
in children with certain types of tumour [23;63]. The primary objective of all the classification
schemes proposed to date has been to identify which patients warrant surgical treatment and
how aggressive such treatment should be. Contrary to early years, when all brainstem tumours
were considered inoperable [21;30;31], for the past thirty years neurosurgeons have been
operating to either de-bulk or completely excise lesions when doing so was felt to be of clinical
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benefit, potentially positively influencing quality of life and/or survival. As stated earlier, that
a subset of patients existed for whom long-term survival was possible has been suspected for
almost eighty years [36;37]. Once again, it was Epstein et al. who first identified diffuse lesions
as being the most rapidly fatal, and focal and cystic lesions as being more amenable to treatment
and long-term survival [27;43;44]. Since then, other prognostic factors have been identified that
can influence the decision to operate (See Table 2).
Factor Studies YearPublished Imaging Comments
Focal (vs. diffuse intrinsic) tumour Sandri et al. [77] 2006 MRI 87.4% 4-year vs. 12.3% 2-year survival
Mauffrey [20] 2006 MRI 90% vs. 22% 2-year survival
Fried et al. 2012 MRI 89% vs. 3% 5-year survival
Cystic appearance Lassiter et al. [34] 1971 notidentified All 4 children with cystic lesions
Prolonged pre-diagnosis
symptoms Fisher et al. [59] 2000 MRI
Cox regression→ survival ↓w/ symptoms > 6 mo (p = .
004)
Shuper et al. [17] 1998 MRI Mean survival 19.5 vs. 12.9 mo with >1 mo symptoms
Other than pons location Fisher et al. [59] 2000 MRI Cox regression→ survival ↓w/ pons involvement (p=.0002)
No presenting eye
symptoms/eye palsies Fisher et al. [59] 2000 MRI Cox regression→survival ↓w/ abducens palsy (p<.0001)
Shuper et al. [17] 1998 MRI Mean survival 17.5 vs. 12.3 mo with no eye symptoms
Basilar artery engulfment Fisher et al. [59] 2000 MRI Cox regression→survival ↓w/ basilar artery engulfed(p=.006)
Tectal location Poussaint et al. [65] 1998 MRI All 32 children with tectal tumours alive
after a mean 5 years follow-up
Non-enhancing on gadolinium
MRI Poussaint et al. [65] 1998 MRI Gadolinium enhancement of tectal lesions
increased odds of disease progression x15
Contrast enhancement on MRI Dellaretti et al. [64] 2012 MRI Mean survival with contrast enhancing lesions = 21.7mo.;
with non-enhancing lesions 54.2 months (p < .001)
Maximum diameter < 0.5 cm Poussaint et al. [65] 1998 MRI Each 1 cm increase in maximum diameter
increased odds of disease progression x5
Neurofibromatosis type 1 Fried et al. [72] 2012 MRI All 7 children with NF-1 had non-focal
lesions & long-term survival
Other papers Numerous isolated anecdotal reports in other papers
Table 2. Factors Predicting Favourable Outcomes in Paediatric Brainstem Tumour Patients
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One of the earliest attempts to empirically look at prognostic factors beyond imaging results
was published by Fisher et al. in 2000 [59]. They reported on the results of a study of 77 patients,
21-years old or younger, seen between 1980 and 1997. In this study, they sought to identify
characteristics statistically associated with poor survival. The factors that they identified were
(a) symptom duration less than six months before diagnosis (p=0.004); (b) abducens palsy at
presentation (p < 0.0001); (c) a pontine location (p=0.0002); and (d) engulfment of the basilar
artery (p=0.006). Twenty of their patients were found to have pilocytic astrocytomas, which
were associated with a very favorable 5-year overall survival rate of 95%, as well as with
location outside the ventral pons (p=0.001) and dorsal exophytic growth (p=0.013). Another
histological type they could predict based upon clinic-radiographic findings was fibrillary
astrocytoma, of which they had 14 cases. These lesions were associated with symptoms < 6
months (p=0. 006), abducens palsy (p < 0.001), engulfment of the basilar artery (p=0.002), and
a one-year survival rate of just 23% (p < 0.0001). Shuper et al. also found, in their analysis of
24 children operated upon between 1981 and 1997, that a shorter duration of symptoms (< 4
weeks) and visual symptoms at presentation were associated with shorter survival and lower
survival rates [17]. Meanwhile, Dellaretti et al. found that contrast-enhancing lesions on MRI
were associated with a significantly shorter mean duration of survival versus non-enhancing
lesions (21.7 vs. 55.2 months, p < 0.001); however, on Cox proportional hazards regression
analysis, tumour grade was the only significant predictor of survival, suggesting that contrast
enhancement in that sample was an indicator of higher tumour grade [64].
Poussaint et al. specifically sought to determine which clinical and imaging findings best
correlated with outcomes in children with tumours involving the midbrain tectum, via a
retrospective review of the medical records and imaging studies of 32 children (16 boys and
16 girls; mean age, 8 years) with tectal tumours [65]. Of this number, eight children had
undergone CT, 11 MRI, and 13 both CT and MRI studies. Over a mean follow-up period of
five years (range, 3.6 months to 17 years), all patients experienced hydrocephalus, for which
all but one required cerebrospinal fluid (CSF) diversion. The tectum was the centre of the
tumour in all cases; and the majority of the tumours appeared iso-dense on CT scans, iso-
intense on T1-weighted MR images, and hyper-intense on T2-weighted images. Twenty
patients required no further treatment. In this group, the mean maximum tumour diameter
was 1.8 cm, and enhancement occurred in only two cases (10%). At follow-up, 18 tumours were
the same size as at baseline, one was larger due to cyst formation in the setting of stable
symptoms, and one was smaller. The remaining 12 patients required further treatment
(excision and/or radiotherapy) because of disease progression, indicated either by increased
tumour size or by worsening symptoms. In this group, the mean maximum tumour diameter
was 2.5 cm and contrast enhancement occurred in nine (75%). Further follow-up in this group
showed decreased tumour size in eight and stable residual tumor in three. The authors then
used regression analysis to calculate and compare the likelihood of a patient requiring further
treatment with various-size enhancing versus non-enhancing tumours and identified two
trends: larger tumours were more likely to require further treatment; and the same was true
for enhancing lesions. Combining these two factors was especially predictive. For example,
whereas 31% of lesions with a maximum diameter of 0.5 cm required further treatment, same-
sized non-enhancing lesions warranted such treatment less than one percent of the time.
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Corresponding percentages for lesions of maximum diameter 1.0, 1.5, 2.0, 2.5, 3.0, 3.5 and 4.0
cm were 48 and 1%, 67 and 3%, 80 and 6%, 90 and 11%, 95 and 21%, 97 and 36%, and 98 and
54%. By the time a lesion reached 4.5 cm in maximum diameter, virtually all (99 and 70%)
required further treatment, irrespective of whether they did or did not enhance. Overall, the
odds of surgical or radiation treatment were almost five times greater for each 1 cm increase
in maximum tumor diameter (odds ratio, 4.9; 95% confidence interval, 1.3-19.3; p=0.015); and
15 times greater when the tumor enhanced versus when it did not (15.0; 2.2-106.5; p < 0.003).
The investigators thereby concluded that, though paediatric tectal tumors exhibit somewhat
variable behavior, patients generally do well, and that larger tumours, and especially those
that that enhance with contrast on MRI, are highly likely to be more aggressive [65]. Whether
size and contrast-based enhancement on MRI or CT predict the need for treatment or ultimate
outcomes with other non-diffuse intrinsic or exophytic brainstem tumours has not yet been
demonstrated.
Another factor long believed to place individuals at increased risk of brainstem and other CNS
malignancies, but also to confer a relatively favorable prognosis, is the presence of type 1
neurofibromatosis (NF-1), though this belief is largely based upon anecdotal reports [66-72].
In the large study of 223 children with brainstem tumours reported by Fried et al., however,
there were seven children with concomitant NF-1; and all had low-grade brainstem tumours
[72]; the statistical likelihood that this occurred merely by chance, assuming a fifty-fifty split
of low-to high-grade lesions (which is roughly what they observed across the sample), is less
than one percent.
Overall in NF-1 patients, brainstem gliomas comprise a heterogeneous group of lesions,
consisting of three main subtypes: (1) diffuse brainstem enlargement; (2) focal enhancing
nodules with or without cystic areas; and (3) peri-aqueductal gliomas. All of these subtypes,
including diffuse brainstem enlargement, generally exhibit a very indolent course and do not
require treatment, though MRI monitoring is indicated until their indolent course is confirmed.
Some lesions even regress on their own [73]. The diffuse brainstem enlargement is somewhat
similar in appearance to the unidentified bright objects (UBOs) that are the most commonly
observed CNS lesions on MRI in patients with NF-1 [74]. Like UBOs, they exhibit abnormal
signals on T1-weighted images. The major differences are that, as opposed to UBOs, there
usually is a mass effect, and these lesions also tend to be considerably larger than most UBOs.
What the diffuse enlargement represents remains controversial. Many presume them to be
gliomas, but they exhibit a much more indolent course than brainstem gliomas seen outside
of NF-1, such that adjuvant treatment is only required in the minority of patients whose lesions
progress. However, ongoing monitoring is required to detect the few who do progress, before
neurological deficits ensue, which often are irreversible. Rarely, these gliomas progress to more
malignant forms of astrocytoma, including glioblastoma [73;75].
The focal enhancing nodules seen in the brainstem of NF-1 patients, which may occur with or
without cystic areas, generally are thought to represent pilocytic astrocytomas, given their
imaging characteristics. Like pilocytic astrocytomas elsewhere, they generally are indolent;
but their course is unpredictable and the brainstem so susceptible to major deficits, relative to
the cerebral hemispheres, that ongoing monitoring is required. Small, focal intrinsic lesions
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may enlarge and then regress spontaneously. Exophytic tumours often are more aggressive
and require treatment.
Periaqueductal gliomas occur adjacent to the aqueduct of Sylvius between the 3rd and 4th
ventricles in the midbrain. They typically manifest with late-onset aqueductal stenosis, leading
to hydrocephalus. Presumably, they represent low-grade gliomas or glial hamartomas, and
typically are indolent. However, because of their location, CSF shunting often is necessary.
But, as with the other two forms of brainstem tumour seen in NF-1 patients, resection usually
is unnecessary [73;75].
Table 3 summarizes currently published research on tumour characteristics that predict a
favourable outcome. What is most evident is the dearth of confirmatory studies. These findings
aside, the brainstem tumour characteristic that is unquestionably the one most likely to
dissuade surgeons from operating is evidence that the tumour is intrinsic and diffuse, due both
to the known high risks of surgery and to the lack of evidence suggesting any benefit, in terms
of either quality of life or survival time [16-18;20]. The corollary to this is that, contrary to thirty
years ago when most surgeons preferred to leave all brainstem tumours alone, focal, exophytic
and cystic tumours are increasingly being accessed and resected, often with good results
[16-18;20;23;60].
Year Study Study subjects 5-year survival
Author(s) Published Type N = N = % =
Lesniak et al. [76] 2003 Retrospective 57 26 45.6%
Sandri et al. [77] 2006 Retrospective 17 15 88.2%
Mauffrey [20] 2006 Retrospective 14 8 57.1%
Teo et al. [63] 208 Retrospective 34 27 79.4%
Fried et al. [72] 2012 Retrospective 108 96 88.9%
Klimo et al. [23] 2013 Retrospective 52 51 98.1%
OVERALL 282 223 79.1%
Table 3. Survival in Paediatric Patients with Non-Diffuse Intrinsic Brainstem Tumours
2.3. Treatment and outcomes
In 1984, Tomita [31] wrote that “radiation therapy is the choice of treatment, should CT indicate
clear evidence of intrinsic brain stem tumor... posterior fossa craniotomy should be undertaken
only for aspiration of cystic intrinsic stem tumors, resection of extra-axial juxtastem tumors
and, although rare, in instances when CT is unable to definitively distinguish extra-axial from
intra-axial mass for verification of lesion location.” Clearly, sentiments have changed; but has
the increase in surgical interventions altered outcomes?
In 1998, Shuper et al. published the results of their study of 24 children with brainstem tumours
operated upon between 1981 and 1997 [17]. The main question they asked was: are we
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improving outcomes? A tissue diagnosis was achieved in only six of the children. Although
the investigators did not perform inferential statistical analysis, average survival in five
patients seen before 1990 was 8.6 months, versus 19.4 months in the five patients seen in 1990
through 1994, and 20.0 months in those seen in 1995 and 1996. Moreover, raw data were
provided, allowing the current author to perform a statistical comparison of months of survival
pre (8.6) versus post (19.7) January 1st 1990. This difference, despite the low numbers, is
significant (t=2.379, df 13, p=0.03). However, these patients generally were offered radiation
+/-chemotherapy, and not surgery. In addition, other biases might have erroneously generated
these results, like alterations in referral patterns or the earlier recognition of tumours as a result
of major technological advances in imaging.
More recently, several authors have reported survival rates in paediatric patients treated
surgically for non-diffuse tumours (Table 3). In 2003, Lesniak et al. [76] retrospectively
reviewed the charts of all pediatric patients admitted to Johns Hopkins University Hospital
with a diagnosis of a brainstem tumor between January 1985 and December 2000: 89 patients
met the inclusion criteria, among whom 57 (64.0%) underwent surgical resection, while 32
(36%) were treated with radiation and/or chemotherapy. Of the surgical candidates, 57 (100%)
had an accompanying MRI scan significant for an enhancing lesion in the midbrain, pons or
the medulla. The pathology was consistent with juvenile pilocytic astrocytoma in 30 patients
(52.6%) and glioblastoma multiforme in 12 patients (21.1%). The remaining cases consisted of
ten patients (17.5%) with fibrillary astrocytomas, three (5.3%) with gangliogliomas, one (1.8%)
with an oligodendroglioma and one (1.8%) with a primitive neuroectodermal tumor. Total
surgical resection was attained in 29 patients, near total resection (>90%) in eight, subtotal
resection (50-90%) in 15, and partial resection (<50%) in five. The progression-free survival of
all patients, which included the twelve with glioblastomas, was 71.9% at 3 years and 45.6% at
5 years. Excluding the 12 patients with known glioblastomas, all of whom died prior to three
years, these survival rates rise to 83 and 53%, comparable to rates observed in a subsequent
study by Sandri et al. [77].
In 2006, Sandri et al. [77] published their series of 31 children admitted to their institution from
1995 to 2003, 14 of whom were classified on MRI as having diffuse and 17 as having focal
brainstem tumours. Patients with diffuse lesions were treated with locoregional radiotherapy
(1.8 Gy/day for 54 Gy) and weekly vincristine for radiosensitization (1.5 mg/sm for six total
doses). Meanwhile, patients with focal tumours underwent surgical resection, with adjunct
chemotherapy and/or radiotherapy considered on a case-by-case basis. Among the 14 with
diffuse tumours, ten experienced a partial response, three exhibited stabilization of their
disease, and one progressed. General and/or neurological symptoms improved in more than
80% of these patients. However, the median time from diagnosis to progression and from
diagnosis to death were just 8 (range of 3-13) and 13 (range of 4-25) months, respectively, with
a 2-year overall survival rate of just 12.3%. Conversely, among the 17 children with focal
lesions, gross total removal was achieved in 4/17 cases, subtotal removal in 7/17, and partial
removal in 6/17. There was one surgery-related death. Eight out of 17 patients had adjuvant
chemo-and/or radiotherapy after progression, among whom six remained free of neurological
symptoms and two died secondary to tumor progression. The 4-year overall and disease-free
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survival rates were 87.4 (SE 8.4) and 58.8% (SE 11.9), respectively, with the extent of resection
identified as the best predictor of survival (p=0.012) [77].
Also in 2006, Mauffrey reported on his retrospectively reviewed series of 27 paediatric patients
admitted to hospital in Turin, Italy with a diagnosis of brainstem glioma [20]. Thirteen patients
had a diffuse pontine tumour on MRI scan, while fourteen had other brainstem gliomas. Those
in the first group had a shorter mean duration of symptoms prior to diagnosis (2.6 vs. 10.6
months), never demonstrated gadolinium enhancement of their tumour on MRI (vs. 78.6% in
the other group), and were much more likely to have symptoms or findings indicating cranial
nerve involvement (77.0 vs. 28.5%). None of the 13 with diffuse gliomas underwent radical
surgery, whereas it was the treatment of choice in the remaining 14. Two-year survival rates
were 25% and 90%, respectively, and 60% of the latter remained alive at five years [20].
In 2008, Teo and Siu [63] reported on their results with 34 consecutive patients between 3 and
16 years of age who underwent endoscope-assisted microsurgery for focal brainstem gliomas
with the intent of radial resection between 1999 and 2005. More than 90% tumour resection
was achieved in 31patients, while >50% was attained in the remainder. There was no peri-
operative mortality and the average follow-up was 46 months. Twenty-three patients (74%)
harboured low-grade and 11 (26%) high-grade gliomas. Kaplan-Meier survival analysis
revealed marked differences in the 5-year survival rates between the two groups (100% vs.
33%). Multivariate analysis demonstrated that the degree of tumour resection was not
associated with poor outcome at 6 months.
Two papers published over the past couple of years are those by Fried et al. [72], based at The
Hospital for Sick Children in Toronto Canada, and Klimo et al., based at George Washington
University in Washington, DC [23]. The latter study, like all those described previously, was
relatively small, with just 52 patients (32 boys), all with radiographically-confirmed, low-grade
focal brainstem gliomas seen from 1986 to 2010. The median duration of follow-up was 10.0
years, and the median age at diagnosis 6.5 years (range 1-17 years). Tumors were located in
the midbrain (n=22, 42%), pons (n=15, 29%), and medulla (n=15, 29%). Surgical extirpation was
the primary treatment in 25 patients (48%). Five-and 10-year event-free survival and overall
survival rates were 59% and 98%, and 52% and 90%, respectively. Surprisingly, children with
intrinsic tumors trended towards slightly higher event-free survival at 5 years than those with
exophytic tumors (p=0.054), but not at 10 years (p=0.147). No other variables were predictive
of event-free survival [23].
The retrospective study by Fried et al. is by far the largest to date, assessing a total of 223
children with brainstem tumours (12% of all CNS tumours seen) followed at The Hospital for
Sick Children in Toronto over the preceding 25 years [72]. Ninety-five of these tumours were
diffuse and an additional 17 were high-grade astrocytomas (grade III or IV). The investigators
made several novel observations. First, whereas 75% of tumors involving the pons were high-
grade, 98% of tumours lacking pontine involvement were low-grade (p = 0.0001). Second,
residual tumour after surgery, even when visualized, did not adversely alter either progres‐
sion-free survival or overall survival. And, among those requiring further treatment, 5-year
progression-free and overall survival were comparable between those receiving chemotherapy
(53 and 93%) and those administered radiotherapy (66 and 83%) (p = 0.26 and 0.30, respective‐
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ly). Among those with focal lesions, five-year progression-free survival (PFS) and overall
survival (OS) were 57% and 89%.
Combining the results of these last seven studies (Table 3), in which children with non-focal
brainstem tumours were identified and treated, either surgically or non-surgically, there were
282 such children, of whom 223 (79.1%) survived long-term (beyond 4 years and most beyond
5 years). In the largest study, which had 108 such children [72], 90% remained alive 10 years
post diagnosis. Several comments are warranted. First, every one of the above-mentioned
studies had significant methodological issues, not the least being that they all were retrospec‐
tive. Moreover, because patients were selected for surgery, it is not possible to rule out the
possibility that the characteristics that made them surgical candidates in the first place (e.g., a
focal vs. diffuse tumour) were responsible for their survival, rather than the surgery itself.
Nonetheless, what is clear is that long-term survival among children with non-diffuse tumours
clearly is not at all uncommon. In fact, it seems likely for four out of five such children, making
it the rule and not the exception, which is radically distant from both the beliefs and outcomes
of thirty and forty years ago, and considerably improved from survival rates in at least one
older study in which those with non-diffuse tumours were identified but not offered surgery
[78]. Fried et al. concluded that children with non-diffuse brainstem tumours do well even
with conservative management; but their conservative management appears to have consisted
of surgical resection in most cases, with adjuvant chemotherapy or radiation considered more
aggressive [72]. Ideally, from a purely methodological standpoint, future studies would
randomize surgery-eligible patients to surgery versus non-surgery groups. Practically,
however, this author considers it unlikely that most parents would consent to allow their
children to be randomly assigned to one group or the other when surgery offers at least the
potential of cure.
The good news, then, irrespective of methodological questions regarding the true effectiveness
of surgery, is that children with several types of brainstem tumour appear to do well. The bad
news is that the majority of brainstem tumours in children continue to be either diffuse intrinsic
lesions or high-grade astrocytomas [72], and the prognosis for either remains dismal, with only
about 10% of children alive two years after diagnosis [79;80]. One major challenge currently
facing researchers and clinicians is to identify non-surgical ways to better target these other‐
wise poorly responsive tumours.
3. Where we are and where we are going
Clearly, the past forty years have brought about substantial changes in the way brainstem
tumours are both perceived and managed. No longer is the term ‘brainstem glioma’ used to
lump all brainstem lesions together as homogenous, untreatable and ultimately fatal. Now,
either three or four heterogeneous classes of tumour are described, and all but one is considered
to be an indication for aggressive, often surgical treatment. Some investigators sub-classify
lesions further, related to their anatomical location (e.g., midbrain, pons, medulla). In essence,
though, irrespective of the number of tumour types proposed, all categorization systems
ultimately separate diffuse intrinsic lesions from all others.
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Current diagnosis largely depends on the use of patient histories and physical findings,
especially paying attention to the duration of symptoms prior to diagnosis and the type(s) of
neurological deficits identified (e.g., ocular palsies), followed by magnetic resonance imaging,
both with and without contrast. Lesions that are intrinsic and diffuse, and lesions that involve
the pons are generally considered to be a contraindication to surgery, though many clinicians
are now biopsying them to determine if they are high-or low-grade to estimate course and
likely survival time [81]. Conversely, lesions that are focal, cystic, and extraphytic are usually
considered treatable, with surgery to remove as much of the tumour as possible often consid‐
ered the treatment of choice. Table 4, utilizing the most recently proposed classification system
of Ramos et al. [61], summarizes current general practices. Following the 2013 publication of
guidelines promoting the biopsy of diffuse intrinsic brainstem lesions to aid in the develop‐
ment of targeted therapies [82], stereotactic biopsies must now be at least considered standard
of care for these patients. Radiation therapy, sometimes combined with chemotherapy,
appears to induce brief clinical remissions in patients with diffuse tumours for whom surgery
is not indicated, and may prolong survival slightly [83]. With other tumours, surgery often
plays the major role; though some patients merely require monitoring and others respond well
to radiation or conservative measures like CSF shunting alone.












Focal Medulla pilocysticastrocytomas Yes Complete resection +/- +/- ≥ 90%
Brainstem gangliocytomas often possible
Dorsal Exophytic Mostly in 4th pilocysticastrocytomas Yes Usually only partial +/- +/- ≥ 90%
ventricle other low-gradeglioma resection is possible
Cervicomedullary Epicentre either pilocysticastrocytomas Yes Complete resection +/- +/- ~ 100%
in medulla or gangliocytomas possible in ~75% ofpts
cervical spine
Focal Tectal Tectum low-grade gliomas Yes Shunt placement Yes Usually not ~ 100%
Resection often
unnecessary
Table 4. Current Management of Paediatric Brainstem Tumours
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There remains no consensus, however, as to how to best categorize lesions; and the lion’s share
of brainstem tumours continue to be considered untreatable and to have a dismal prognosis.
Consequently, three major challenges that remain are (1) coming to some consensus as to
classifying lesions, so as to best predict their course, likely response to treatment and, hence,
when and how best to treat them; (2) developing more effective non-surgical treatments to
treat the intrinsic diffuse tumours for which all current treatments, including surgery, have
been ineffective and the prognosis remains abysmal; and (3) optimizing quality of life in these
children and their families, irrespective of long-term prognosis. With a view to these three
main objectives, we now briefly explore current and future directions in the detection,
diagnosis and classification of brainstem tumours, and in their non-operative and operative
management.
3.1. Enhanced diagnostics and classification
In few fields have there been as many and as dramatic advances as in the field of diagnostic
imaging, and this appears to be having a significant impact upon how brain and brainstem
tumours are now detected and diagnosed. Increasing recognition that not all brainstem
tumours are a diverse collection of pathological entities with distinct courses and responses to
treatment, has led to attempts to distinguish between them using advanced imaging. Typically,
for example, diffuse intrinsic fibrillary astrocytomas appear hypo-intense on T1-weighted
images, while heterogeneously hyper-intense on T2-weighted images; they also exhibit
indistinct margins that reflect the tumour’s highly infiltrative nature [61]. Beyond distinctions
made using different MR sequences, various contrasts are now being used to try to detect
lesions that otherwise might be missed [84] and to delineate low-from high-grade lesions [19;
45;56;64;76]. For example, dorsal exophytic tumours often are low-grade pilocytic astrocyto‐
mas that, like high-grade fibrillary astrocytomas, may be hypo-intense on T1-weighted images
and hyper-intense on T2-weighted images; however, they classically appear well-demarcated.
Moreover, after gadolinium infusion, a cystic component often is identified, as only the solid
portion of the tumour is enhanced, revealing a hypo-intense centre [61;85;86]. More recent
advances in MR scanning — like MR spectroscopy, MR perfusion, and diffusion tensor
imaging (DTI) — are also being utilized to further establish the histopathologic diagnosis of
brainstem lesions [18;61]. An additional advantage of these newer MR technologies is that they
are better at monitoring for disease recurrence or progression after treatment, since radiation-
induced necrosis may be mistaken for tumour re-growth with traditional MRI [87-90]. In
addition, functional scans — like functional MRI (fMRI), positron emission tomography (PET),
and single-photon emission computed tomography (SPECT) — are emerging as additional
imaging tools to identify and characterize lesions in the brain, brainstem and spinal cord
[19;91-95]. Further development of these tools may aid in further delineating the various
brainstem tumours, even obviating the need for tissue in those patients for whom biopsies
pose undue risk.
This being said, among the most major imaging advances related to brainstem tumours relates
to stereotactic biopsies. A stereotactic biopsy utilizes a computer and images performed in at
least two planes, first to localize a target lesion, like a tumour, in three-dimensional space; then
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to determine its depth; and finally to guide the removal of tissue for pathological examination.
Stereotactic biopsies rely on the underlying principle of parallax, a process that initially was
used in astrology to estimate distances between stars [96]. Parallax is the concept of using
multiple site lines to visualize the same object relative to objects of known position in front of
and behind it. Since objects closer to the observer tend to move more than objects that are more
distant when the point of observation changes, measuring the degree of movement of the target
lesion relative to reference points, combined with recording the change in viewing angle,
permits one to estimate the depth or "Z-dimension" of the target lesion [97]. Long used to aid
in the biopsy of breast lesions [98], CT-guided stereotactic biopsies have been used for the
diagnosis of brain lesions since the nineteen seventies [99;100], but not with brainstem lesions
until more recently. Just this year, Cage et al. reported on their results specifically biopsying
diffuse brainstem tumours; they also extensively reviewed the literature [81]. In their own
series, nine children with pontine lesions were biopsied, with successful tissue collection
achieved in all cases. Among these lesions, four were found to be low-grade (grade I or II)
astrocytomas, and five high-grade (grade III or IV) gliomas, demonstrating heterogeneity even
among diffuse pontine lesions. Moreover, only one patient experienced any post-operative
complication – transient seizures and hydrocephalus. In their review of the literature, the same
authors identified twenty case series besides their own, ranging in size from a single paediatric
patient [101] to 52 children [102]. In this latter series, among 52 paediatric brainstem biopsies,
only five patients experienced any post-operative morbidity, in four instances transient; and
there were no deaths. Biopsy was felt to alter management in 18% of the cases. In another one
of the larger series, Kondziolka and Lunsford reported on their use of CT-guided stereotactic
biopsies in 40 consecutive patients seen over a 13-year interval [103]. Of this number, 20
patients had midbrain lesions (n=20), 18 pontine lesions, and two medullary lesions. Midline
lesions were approached via a coronal, trans-thalamic trajectory; lateral brain stem lesions
usually were approached via a trans-cerebellar route. A histologic diagnosis was achieved in
38 patients (95%), and no post-biopsy haemorrhages were noted on CT performed immediately
after the procedure. Only one patient (2.5%) experienced a complication, which was transient
diplopia. Altogether across the twenty-one papers Cage et al. reviewed, there were 294
documented brainstem biopsies in paediatric patients, among whom there were 16 cases of an
intra-operative complication (5.4%); 42 cases of increased post-operative morbidity (14.3%)
that was transient in the vast majority of cases; 29 inconclusive biopsies (9.9%); and two
procedure-related deaths (0.7%) [102]. The authors concluded that brainstem biopsies are safer
than widely perceived and that, when used judiciously, might be both safe and of advantage
in terms of determining treatment. Stereotactic biopsies have been demonstrated to be superior
to MRI alone in accurately diagnosing brainstem lesions [104].
3.2. Enhanced non-operative management
Many have argued against biopsying diffuse intrinsic brainstem lesions, since they cannot be
surgically removed or even de-bulked without causing unacceptable neurological deficits
because of their location and infiltrating nature, and given the lack of enduring response that
the vast majority of patients demonstrate to traditional chemotherapy and radiation. But this
pessimistic outlook may be changing, given emerging knowledge about potential therapeutic
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targets and optimized ways to cross the blood-brain barrier. In fact, one key rationale behind
obtaining tissue in patients with diffuse pontine lesions stems from recent work to further
classify lesions based upon a number of identifiable genetic and molecular alterations that may
render these tumors susceptible to targeted therapies [79-81].
Until the last couple of years, the biology of diffuse intrinsic brainstem tumours was entirely
unknown. However, tissue analysis has now identified a number of identifiable genetic and
molecular alterations — like amplification of receptor tyrosine kinases and cell-cycle regula‐
tory genes, and alterations in membrane proteins and the Hedgehog (Hh) signaling pathway
[79;105-109] — that could serve as therapeutic targets. Much of this research is being aided by
the development of human glioma cell lines that can be studied in the lab [110]. One particular
membrane protein that has garnered considerable recent interest is B7-H3 (also called CD276),
a type I trans-membrane glycoprotein that is part of the B7-CD28 family [111]. This glycopro‐
tein is known to interact with host defenses in certain cancers, being recognized by the
monoclonal antibody 8H9 [112] that binds to a vast array of different tumours. Among primary
brain tumors, for example, it bound to 15 of 17 glioblastomas, three of four mixed gliomas, and
six of eight astrocytomas, among others; however, it did not bind to normal neurons or glial
cells [113]. Moreover, extremely favourable results were observed in a study in which 21
children with recurrent stage IV neuroblastoma — like gliomas, a neuroectodermal tumor —
were administered compartmental intra-thecal antibody-based radio-immunotherapy [114].
The therapy consisted of 131I-monoclonal antibodies targeting B7-H3. Among the 21 children
treated, 17 (81%) remained alive between seven and 74 months later (median 33 months),
significantly longer than the expected, post-disease-recurrence median survival of six months.
For all these reasons, the potential is there for B7-H3 to be a future therapeutic target for diffuse
intrinsic brainstem gliomas. Considerable interest also has focussed on the epidermal growth
factor receptor (EGFR), which has been the target of several chemotherapeutic drugs currently
undergoing early phase trials, like gefitinib and erlotinib [115-117]. Another drug currently
undergoing early phase testing is vandetanib, a tyrosine kinase inhibitor of both the EGFR and
vascular endothelial growth factor receptor (VEGFR) [118]. To date, one-year survival rates
have ranged from 38 to 56% [115-118], not significantly better than the median survival of 9 to
12 months reported elsewhere [79].
Promising results were observed when data were combined across four phase II trials [119] in
which 18 mostly paediatric (age range 2 – 42 years, median=10) patients with brainstem
gliomas were treated with anti-neoplaston A10 (A10I) and AS2-1 injections over a median of
five months [120]. Fourteen of the 18 patients had diffuse intrinsic tumors; four were glioblas‐
tomas and 14 anaplastic gliomas. Prior to treatment, twelve patients had suffered a relapse
and six had never received either radiation or chemotherapy. Contrary to the expected 2-year
survival rate of roughly 10%, 39% remained alive at two years, and 22% at five years, including
one patient with an anaplastic astrocytoma who remained alive for 17 years and another with
a glioblastoma for more than five years. The only adverse event was a single case of reversible
anaemia.
Another potential boon to the treatment of all CNS malignancies may be the development of
nanotherapeutic approaches, which include an entire new generation of novel targeted-
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delivery devices — ‘smart’ nanoparticles — that facilitate the transfer of a variety of therapies,
from drugs to thermotherapy, across the blood-brain barrier [121], a barrier that has tradi‐
tionally hampered the delivery of most anti-neoplastic drugs. Stem cells that are themselves
drawn to tumour cells are another potential vehicle that is being explored for the treatment of
high-grade gliomas [122;123] and may have applications in the treatment of inoperable
brainstem gliomas. Some investigators are also examining the potential to test the effectiveness
of anti-neoplastic drugs ex vivo prior to patient administration via the use of in vitro assays
[124]. In this way, drug regimens might be more appropriately taylorized to each patient, and
in vivo drug effectiveness more accurately predicted prior to initiating therapy, thereby
minimizing unnecessary toxicity and enhancing the likelihood of initial treatment response.
Finally, as mentioned earlier, advanced imaging techniques are now allowing for enhanced
prospective monitoring of treatment response and the earlier detection of disease recurrence
and progression [87;88]. Another previously-unexplored means by which to accomplish such
monitoring might be via the analysis of various bodily fluids — like blood, urine and cere‐
brospinal fluid (CSF) — to identify and estimate levels of various CNS tumour markers, similar
to how prostate-specific antigen (PSA) is being used to detect and monitor prostate cancer. For
example, Saratsis et al. recently performed protein profiling by mass spectrometry of 76
specimens — including CSF, serum, urine, and normal and tumor brainstem tissue [125] —
from 10 patients with diffuse intrinsic brainstem gliomas and four healthy controls. CSF
proteomic analysis revealed selective up-regulation of both cyclophillin A (CypA) and
dimethylarginase 1 (DDAH1) in patients relative to controls. Protein expression was validated
further via Western blot analysis and immunohistochemical assays. Immunohistochemical
staining exhibited selective up-regulation of secreted but not cytosolic CypA and DDAH1 in
patients. The authors proposed that the detection of secreted CypA and DDAH1 in serum and
urine could have clinical applications in the monitoring of treatment response and disease
recurrence in patients with brainstem gliomas [125].
As such, although the prognosis for patients with inoperable brainstem gliomas remains bleak
for the time being, beliefs regarding the potential for enhanced survival certainly are changing
with the emergence of targeted therapies, better delivery systems, and enhanced imaging and
other techniques to monitor disease regression and progression. But what will the neurosur‐
geon’s role be in all this?
3.3. Emerging role of the neurosurgeon in the management of diffuse brainstem tumours
Nothing has changed in terms of neurosurgeons’ reluctance to operate on diffuse intrinsic
brainstem gliomas; nor does it seem likely to anytime soon, given the known aggressiveness
of the vast majority of these tumours, their high degree of infiltration that would preclude
anything more than partial resection, and the extreme risks of such surgery, given the
anatomical compactness of vital structures and neural pathways. Consequently, the main
change in current surgical practices relates to the stereotactic biopsy of these lesions, a practice
that this year was formally recommended in a published, multi-disciplinary consensus
statement concerning surgical approaches to low-and high-grade astrocytomas and diffuse
intrinsic pontine gliomas in childhood [82].
Tumors of the Central Nervous System – Primary and Secondary48
There also has been a clear swing in the route selected for brainstem biopsy access, at least in
studies involving paediatric patients. For example, over the decade of the nineteen nineties,
82% of reported brainstem biopsies were accessed via a trans-frontal route, versus just 18%
trans-cerebellar. Since the year 2000, however, these percentages have completely reversed,
with 82% of reported biopsies trans-cerebellar and 18% trans-frontal. In the five studies
published since 2006 in which paediatric patients were identified among those biopsied
[81;126-129], every one of the ninety biopsies were performed through the cerebellum. Across
these ninety biopsies, 77 of them in children, there was one intra-operative complication (1.1%),
nine post-operative complications (10%), two inconclusive biopsies (2.2%) and no deaths. The
reason(s) for this shift in surgical approach is not entirely clear. In 2012, Dellaretti et al.
published the results of their study comparing the two approaches over twenty-three years of
practice (1984-2007), and no significant differences were noted [130]; however, whether any
children were included within the sample of 142 patients is not stated in the manuscript.
Moreover, there was a clear preference for trans-frontal biopsies, which were performed in
123 of the patients versus just 19 via the cerebellum, and no explanation for this preference
was offered.
Cage et al. described their trans-cerebellar surgical approach in nine children with diffuse
intrinsic brainstem tumours as follows [81]: “Preoperatively, patients all completed an MRI
with and without gadolinium intravenous contrast of the brain according to Brainlab (Brainlab
AG, Germany) protocols to allow for intraoperative neuronavigation. Patients were positioned
either supine (n=3) or in the lateral decubitus position (n=6) opposite the side of their lesion
with neck flexion in the same direction. The head was then fixed using both a horseshoe head-
holding device and further immobilized with Mayfield pin fixation. For all stereotactic
procedures, the Brainlab neuronavigation system was used to plan the trajectory from the skull
to target locations in the brainstem. The biopsy entry point was transcerebellar, either right
(n=4) or left (n=5) for all patients. A side-cutting biopsy needle was then passed along the
trajectory path. Between one and four samples were obtained from within the lesion.... Target
selection was designed to minimize the trajectory through the brainstem. If there was an
obvious area of enhancement suggesting a pathologically-aggressive area of the tumour, then
this was chosen as the biopsy target. Otherwise, the target was usually just deep to the
cerebellar peduncle. Care was taken to avoid the lateral edge of the fourth ventricle and the
ventral corticospinal tracts.” [81]
Otherwise, surgeons continue to operate successfully on patients with focal, exophytic and
cystic brainstem tumours, with survival and quality of life enhanced even by subtotal resec‐
tions, as well as by cyst drainage procedures and the insertion of shunts when necessary [61].
But here too, stereotactic biopsies play a significant role, as some apparent tumours are found
to be focal areas of inflammation, infectious lesions, vascular anomalies, or some other
pathology necessitating different treatment [29;131]. As such, neurosurgeons now appear to
have a role to play in all paediatric patients with brainstem tumours, a far cry from forty years
ago, when they seemed to have no role at all.




Over the past forty years, much has changed in the way in which brainstem tumours are treated
in children. Though these lesions continue to be the most common cause of CNS cancer-related
death in the paediatric population, the discovery of a brainstem tumour is no longer a death
sentence. Formerly thought to be pathologically homogeneous and/or of no pathological
interest since they were not surgically accessible, paediatric brainstem tumours are now
understood to be highly heterogeneous; and knowing the pathology is now considered critical
to management decisions. For the minority of children who have focal, exophytic or cystic
lesions, long-term survival is now the rule, with 5-and 10-year survival rates often 90% or
higher. For those children in the future who will develop diffuse brainstem lesions, mostly
high-grade gliomas, emerging therapies are now providing multiple reasons to hope. Besides
providing competent, compassionate care to each child and their families, what is critical, from
the current neurosurgeon’s standpoint, is to assist in the collection of tissue, either by biopsy
while a child is alive, or at autopsy via respectful conversations with parents and other
caregivers, so that future targeted therapies can be developed, tested and ultimately approved
for widespread use.
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